Newswire (Published: Monday, April 24, 2017, Received: Thursday, April 20, 2017, 7:26:21 PM CDT)

Word Count: 400

Jules Bordet Institute Reports Findings in Prostate Cancer (Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting out of Brussels, Belgium, by NewsRx editors, research stated, "Following new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice for those patients."

Our news journalists obtained a quote from the research from Jules Bordet Institute, "These variables are summarized and discussed in detail. High radiation doses to the prostate are essential to achieve good local control in patients with high-risk nonmetastatic disease. Addition of androgen deprivation therapy (ADT) to radiation therapy has significantly improved overall survival and cancer-specific survival compared with radiation therapy alone without significantly increasing toxicity. Long-term neo(adjuvant) ADT (2-3 years) to radiation therapy significantly improved cancer-specific survival compared with short-term ADT (4-6 months). Radical prostatectomy with extended pelvic lymph node dissection is considered a reasonable option in experienced hands. ADT alone is an inappropriate treatment option for patients with high-risk nonmetastatic disease."

According to the news editors, the research concluded: "Management decisions for these patients should be discussed by a multidisciplinary team."

For more information on this research see: Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. Therapeutic Advances In Urology, 2017;9(3-4):73-80. (Sage Publications - www.sagepub.com/; Therapeutic Advances In Urology - tau.sagepub.com)

Our news journalists report that additional information may be obtained by contacting F. Aoun, Dept. of Urology, Jules Bordet Institute, Universite Libre de Bruxelles, 1 Rue Heger Bordet, 1000 Brussels, Belgium. Additional authors for this research include A. Bourgi, E. Ayoub, E. El Rassy, R. van Velthoven and A. Peltier (see also Oncology - Prostate Cancer).

Keywords for this news article include: Europe, Belgium, Brussels, Oncology, Androgens, Article Review, Prostate Cancer, Clinical Research, Radiation Therapy, Drugs and Therapies, Prostatic Neoplasms, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Western Europe
Belgium
Europe
Brussels

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
      Treatments and Therapies
            Medicinal Drugs